natgillin/translations-raw huggingface dataset:
A total daily dose of 300 mg Zavesca administered in three divided doses was used in the above two studies.
Kahes eelpool kirjeldatud uuringus kasutati päevase annusena 300 mg Zavesca’t, mis jaotati kolme võrdsesse ossa.
A total of 1,006 patients with KPS≥60 were randomized to the following treatment groups:
Kokku 1006 patsienti, kelle KPS≥60, randomiseeriti järgmistesse ravigruppidesse:
A total of 1,010 patients refractory to chemotherapy were randomised 1:1 to receive Vectibix or cetuximab to test whether Vectibix is non-inferior to cetuximab.
1010 patsienti, kes olid refraktoorsed keemiaravile, randomiseeriti Vectibix’i või tsetuksimabi rühma suhtega 1:1, et uurida Vectibix’i samaväärsust tsetuksimabiga.
A total of 1,106 patients were randomised, 553 to each arm.
Kokku randomiseeriti 1106 patsienti, 553 kumbagi rühma.
A total of 1,188 patients with relapsing remitting MS (RRMS) treated with LEMTRADA (12 mg or 24 mg) constituted the safety population in a pooled analysis of controlled clinical studies resulting in 2,363 patient- years of safety follow-up and a median follow-up of 24 months.
Kontrollitud kliiniliste uuringute koondandmete analüüsi ohutuspopulatsioon koosneb 1188 ägenemiste ja remissioonidega kulgeva hulgiskleroosiga (RRMS) patsiendist, keda raviti LEMTRADA’ga (12 mg või 24 mg), andes tulemuseks 2363 patsiendiaasta pikkuse ohutuse kontrollperioodi ja jälgimisperioodi mediaanseks kestuseks 24 kuud.
A total of 1,505 alemtuzumab patients were exposed in these trials.
Kliinilistes uuringutes manustati alemtuzumabi kokku 1505 patsiendile.
A total of 1,620 babies took part in this study.
Selles uuringus osales kokku 1620 väikelast.
A total of 1,732 subjects continued into the second 2-year extension (bazedoxifene 20 mg: n=560, bazedoxifene 40/20 mg: n=582, and placebo: n=590).
Kokku jätkas teises kaheaastases jätku- uuringus 732 patsienti (basedoksifeen 20 mg: n=560, basedoksifeen 40/20 mg: n=582, platseebo: n=590).
A total of 1.106 patients were randomised, 553 to each arm.
Kokku randomiseeriti 1106 patsienti, 553 kumbagi rühma.
A total of 1.25x1011 bacteria of the following strains:
Kokku 1,25x1011 bakterit järgmistest tüvedest:
A total of 1.25x1011 bacteria of the following strains:
Kokku 1.25x1011 bakterit järgmistest tüvedest:
A total of 10 mg of Votubia dispersible tablets per glass must not be exceeded.
Mitte ületada Votubia dispergeeruvate tablettide koguannust 10 mg klaasi kohta.
A total of 10 mg of Votubia dispersible tablets per syringe must not be exceeded.
Mitte ületada Votubia dispergeeruvate tablettide koguannust 10 mg süstla kohta.
A total of 10 paediatric patients with ages 12 to 16 years who had resolving infections were given single doses of either dalbavancin 1000 mg (body weight ≥ 60 kg) or dalbavancin 15 mg/kg (body weight < 60 kg).
Kokku kümnele 12–16-aastasele pediaatrilisele patsiendile, kellel oli taanduv infektsioon, anti ühekordne annus 1000 mg dalbavantsiini (kehakaalu ≥60 kg korral) või 15 mg/kg dalbavantsiini (kehakaalu <60 kg korral).
A total of 10 PAH subjects enrolled and completed the study.
Uuringusse kaasati ja selle lõpetas kokku kümme PAH-ga patsienti.
A total of 10 patients received PE/PI prior to eculizumab.
Kokku 10 patsienti raviti enne ekulizumabi PE/PI- ga.
A total of 10,795 patients were treated in 6 actively controlled VTE prevention trials with at least one dose of the medicinal product.
Kuus aktiivselt kontrollitud VTE profülaktika uuringut hõlmasid kokku 10 795 patsienti, kellele manustati vähemalt üks annus uuritavat ravimit.
A total of 1006 patients with KPS ≥ 60 were randomized to the following treatment groups:
Kokku 1006 patsienti KPS ≥ 60 randomiseeriti järgmistesse ravigruppidesse:
A total of 1006 patients with KPS ≥ 60 were randomized to the following treatment groups:
Kokku 1006 patsienti KPS  60 randomiseeriti järgmistesse ravigruppidesse:
A total of 1006 patients with KPS ≥60 were randomized to the following treatment groups:
Kokku 1006 patsienti KPS ≥ 60 randomiseeriti järgmistesse ravigruppidesse:
A total of 1006 patients with KPS  60 were randomized to the following treatment groups:
Kokku 1006 patsienti KPS  60 randomiseeriti järgmistesse ravigruppidesse:
A total of 1006 patients with KPS≥60 were randomized to the following treatment groups:
Kokku 1006 patsienti, kelle KPS≥60, randomiseeriti järgmistesse ravigruppidesse:
A total of 1006 patients with KPS≥60 were randomized to the following treatment groups:
Kokku 1006 patsienti, KPS ≥60, randomiseeriti järgmistesse ravigruppidesse:
A total of 102 severe familial hypercholesterolaemia patients and 96 homozygous familial hypercholesterolaemia patients enrolled in TAUSSIG.
Uuringusse TAUSSIG kaasati kokku 102 raske päriliku hüperkolesteroleemiaga patsienti ja 96 homosügootse päriliku hüperkolesteroleemiaga patsienti.
A total of 104 patients were randomised to treatment in this trial, 53 to Avastin 10 mg/kg every 2 weeks plus placebo and 51 to Avastin 10 mg/kg every 2 weeks plus erlotinib 150 mg daily.
Selles uuringus randomiseeriti ravi saama kokku 104 patsienti, 53 patsienti määrati saama Avastin’i annuses 10 mg/kg iga 2 nädala järel pluss platseebot ning 51 patsienti Avastin’i annuses 10 mg/kg iga 2 nädala järel pluss erlotiniibi 150 mg ööpäevas.
A total of 107 patients received treatment of whom 52 % were female, 89 % Caucasian, 67 % with HCV Genotype 1 and 63 %
Ravi sai kokku 107 patsienti, kellest 52% olid naissoost, 89% heledanahalised, 67%-l oli HCV genotüüp 1 ja 63% olid
A total of 1072 patients were randomised (1:1) to receive either Cyramza (n=536) at 8 mg/kg or placebo (n=536), in combination with FOLFIRI.
Kokku randomiseeriti 1072 patsienti (1:1) saama kas Cyramza’t (n=536) annuses 8 mg/kg või platseebot (n=536) koos FOLFIRI-ga.
A total of 1078 patients responded to induction therapy, of which 1018 were randomised to MabThera maintenance therapy (n=505) or observation (n=513).
Kokku 1078 patsienti reageeris induktsioonravile, kellest 1018 randomiseeriti MabThera säilitusravi gruppi (n=505) või vaatlusgruppi (n=513).
A total of 11 of 31 (36%) patients in the weekly treatment group versus 5 of 31 (16%) patients in the placebo group had an increase in FEV1 of at least 0.02 l at or before the end of the study, indicating a dose-related improvement in airway obstruction.
Kokku 11-l patsiendil 31-st (36%) iganädalase ravi rühmas ja 5-l patsiendil 31-st (16%) platseeborühmas suurenes forsseeritud ekspiratoorne sekundimaht uuringu lõpuks või enne selle lõppu vähemalt 0,02 l võrra, mis näitas hingamisteede obstruktsiooni annusest sõltuvat paranemist.
A total of 11,250 patients with type 2 diabetes were treated in 10 double-blind, placebo- and active-controlled clinical studies, of which 7,015 received empagliflozin (empagliflozin 10 mg: 3021 patients; empagliflozin 25 mg: 3994 patients).
Kokku raviti 10. topeltpimedas platseebo ja toimiva ravimiga kontrollitud kliinilises uuringus 11 250 2. tüüpi suhkurtõvega patsienti, kellest 7 015 said empagliflosiini (empagliflosiin 10 mg:
A total of 112 (64%) patients received subsequent crizotinib treatment.
Kokku jätkas 112 (64%) patsienti seejärel krisotiniibraviga.
A total of 114 patients with previously treated chronic ITP were randomised 2:1 eltrombopag (n=76) to placebo (n=38).
Kokku 114 eelnevalt ravitud kroonilise ITP-ga patsienti randomiseeriti 2:1 saama eltrombopaagi (n = 76) või platseebot (n = 38).
A total of 116 patients were randomised to receive bevacizumab 3 mg/kg every 2 weeks (n=39), 10 mg/kg every 2 weeks; (n=37), or placebo (n=40).
Kokku 116 patsienti randomiseeriti saama bevatsizumabi 3 mg/kg iga 2 nädala järel (n=39), 10 mg/kg iga 2 nädala järel (n=37) või platseebot (n=40).
A total of 117 patients were randomised, 78 to Votubia and 39 to placebo.
Kokku randomiseeriti 117 patsienti – 78 Votubia- ja 39 platseeborühma.
A total of 117 patients were treated with somatropin; 36 received somatropin 0.125 mg/kg three times a week and 81 patients received 0.054 mg/kg somatropin daily.
Kokku raviti somatropiiniga 117 patsienti: 36 said somatropiini 0,125 mg/kg/ kohta 3 korda nädalas ja 81 patsienti said 0,054 mg/kg/ kohta päevas.
A total of 121 patients were treated and evaluable for efficacy (90 with Eylea).
Kokku raviti 121 patsienti (90 patsienti Eylea’ga), kes kõik vastasid efektiivsuse hindamise tingimustele.
A total of 1226 patients were randomised (1:1) to receive either ZALTRAP (N=612; 4 mg/kg as a 1 hour intravenous infusion on day 1) or placebo (N=614), in combination with 5-fluouracil plus irinotecan [FOLFIRI: irinotecan 180 mg/m2 intravenous infusion over 90 minutes and folinic acid (dl racemic) 400 mg/m² intravenous infusion over 2 hours at the same time on day 1 using a Y-line, followed by 5-FU 400 mg/m² intravenous bolus, followed by 5-FU 2400 mg/m² continuous intravenous infusion over 46-hours].
Kokku 1226 patsienti jagati juhuvalikuna suhtes 1:1 saama ravi ZALTRAP’iga (N=612; 4 mg/kg 1-tunnise intravenoosse infusioonina 1. päeval) või platseebot (N=614), mõlemad kombinatsioonis 5-fluorouratsiili ja irinotekaaniga (FOLFIRI: irinotekaan 180 mg/m2 intravenoosse infusioonina 90 minuti jooksul ja foliinhape (dl-ratseemiline) annuses 400 mg/m2, manustatuna intravenoosse infusioonina 2 tunni jooksul samal, 1. päeval, kasutades Y-infusioonisüsteemi, millele järgneb 5-FU annuses 400 mg/m2 intravenoosse boolusena ja seejärel 5-FU annuses 2400 mg/m2 intravenoosse püsiinfusioonina 46 tunni jooksul.
A total of 13 out of 83 subjects who participated in pivotal study developed an antibody capable of binding to recombinant human hyaluronidase (rHuPH20) at least once during the clinical study.
Olulises uuringus osalenud 83-st inimesest 13-l tekkisid kliinilise uuringu ajal vähemalt üks kord antikehad, mis suutsid seonduda rekombinantse inimese hüaluronidaasiga (rHuPH20).
A total of 1324 patients enrolled in OSLER.
OSLER-uuringusse kaasati kokku 1324 patsienti.
A total of 14,779 patients with type 2 diabetes mellitus, including 6,448 patients treated with 25 mg alogliptin and 2,476 patients treated with 12.5 mg alogliptin, participated in one phase 2 or 13 phase 3 (including the cardiovascular outcomes study) double-blind, placebo- or active-controlled clinical studies conducted to evaluate the effects of alogliptin on glycaemic control and its safety.
Kokku 14 779 patsienti 2. tüüpi suhkurtõvega, sealhulgas 6448 patsienti, keda raviti 25 mg alogliptiiniga, ja 2476 patsienti, keda raviti 12,5 mg alogliptiiniga, osales ühes II faasi või 13-s III faasi (sealhulgas südame-veresoonkonnaga seotud ravitulemuste uuring) topeltpimedas, platseebo- või aktiivse ravimiga kontrollitud kliinilises uuringus, mis viidi läbi alogliptiini toimete uurimiseks glükeemilisele kontrollile ja selle ohutuse hindamiseks.
A total of 14.3% of patients receiving apremilast had observed weight loss between 5-10% while 5.7% of the patients receiving apremilast had observed weight loss greater than 10%.
Kokku 14,3% patsientidest, keda raviti apremilastiga, oli kehakaalu langus 5%...10%, ning 5,7% patsientidest, keda raviti apremilastiga, oli kehakaalu langus rohkem kui 10%.
A total of 1473 children (including otherwise healthy children aged 1-12 years old and asthmatic children aged 6-12 years old) participated in clinical studies of oseltamivir given for the treatment of influenza.
Kliinilistes uuringutes, kus oseltamiviiri kasutati gripi raviks, osales kokku 1473 last (sh muidu terved 1...12- aastased lapsed ja 6...12-aastased astmaga lapsed).
A total of 1493 patients were randomised and treated with either placebo, apremilast 20 mg or apremilast 30 mg given orally twice daily.
Kokku randomiseeriti 1493 patsienti, kellele manustati platseebot või apremilasti 20 mg või 30 mg kaks korda ööpäevas suu kaudu.
A total of 15 paediatric patients (aged 2 months to 12 years) received Soliris in aHUS Study C09- 001r.
aHUS’i uuringus C09-001r said Soliris’ega ravi kokku 15 last (vanuses 2 kuud kuni alla 12 eluaasta).
A total of 152 children (1 month to < 16 years of age) were treated with brivaracetam in a pharmacokinetic study and the related follow up study.
Farmakokineetilises uuringus ja sellega seotud jätku-uuringus raviti brivaratsetaamiga kokku 152 last (vanuses 1 kuu kuni alla 16 eluaasta).
A total of 158 children received the recommended dose of oseltamivir once daily in a post-exposure prophylaxis study in households (n = 99), a 6-week paediatric seasonal prophylaxis study (n = 49) and a 12- week paediatric seasonal prophylaxis study in immunocompromised subjects (n = 10).
Kokkupuutejärgse profülaktika uuringus perekondades (n = 99), 6-nädalases laste sesoonse profülaktika uuringus (n = 49) ja 12-nädalases laste sesoonse profülaktika uuringus immuunpuudulikkusega isikutel (n = 10), sai kokku 158 last oseltamiviiri soovitatavas annuses üks kord päevas.
A total of 16 patients (4.4%) were  75 years old.
Kokku 16 patsienti (4,4%) olid > 75-aastased.
A total of 166 patients in the crizotinib arm and 163 patients in the chemotherapy arm had completed the EORTC QLQ-C30 and LC13 questionnaires at baseline and at least 1 postbaseline visit.
Küsimustikud EORTC QLQ- C30 ja LC13 oli täitnud enne ravi alustamist ja vähemalt ühel visiidil pärast ravi alustamist krisotiniibi rühmas kokku 166 patsienti ja keemiaravi rühmas 163 patsienti.
A total of 169 patients (47.1%) completed ≥ 6 cycles maintenance treatment with ALIMTA, representing at least 10 total cycles of ALIMTA.
Kokku lõpetas ≥ 6 tsüklilise säilitusravi ALIMTA’ga 169 patsienti (47,1%), mis kokku moodustas vähemalt 10 tsüklit ALIMTA’ga.
A total of 1717 asymptomatic or mildly symptomatic chemotherapy-naive patients were randomized 1:1 to receive either enzalutamide orally at a dose of 160 mg once daily (N = 872) or placebo orally once daily (N = 845).
Kokku 1717 asümptomaatilist või kergelt sümptomaatilist varem kemoteraapiat mittesaanud patsienti randomiseeriti suhtes 1:1 saama kas suukaudset ensalutamiidi annuses 160 mg üks kord ööpäevas (N = 872) või suukaudset platseebot üks kord ööpäevas (N = 845).
A total of 173 patients subsequently enrolled in an extension trial in which patients received 2 mg/kg of elosulfase alfa every week or 2 mg/kg every other week, and then all were switched to 2 mg/kg every week upon availability of the Week 24 results.
Kokku 173 patsienti kaasati hiljem jätku-uuringusse, kus patsiendid said 2 mg alfaelosulfaasi kehakaalu 1 kg kohta üks kord nädalas või 2 mg Vimizimi kehakaalu 1 kg kohta iga kahe nädala järel, seejärel määrati kõik patsiendid pärast
A total of 1774 patients received avanafil, which was taken as needed at doses of 50 mg (one study), 100 mg and 200 mg (four studies), respectively.
Kokku 1774 patsienti said avanafiili, mida võeti vajaduse korral annuses vastavalt 50 mg (üks uuring), 100 mg ja 200 mg (neli uuringut).
A total of 1774patients received avanafil, which was taken as needed at doses of 50 mg (one study), 100 mg and 200 mg (four studies), respectively.
Kokku 1774 patsienti said avanafiili, mida võeti vajaduse korral annuses vastavalt 50 mg (üks uuring), 100 mg ja 200 mg (neli uuringut).
A total of 18 patients with ADA-SCID were treated with Strimvelis as part of one open-label pivotal trial (AD1115611; N=12), two early open-label pilot studies (AD1117054/AD1117056; N=3), and a compassionate use program (AD1117064; N=3).
Osana ühest avatud olulisest uuringust (AD1115611; N=12), kahest varajasest avatud pilootuuringust (AD1117054/AD1117056; N=3) ja ravimi tasuta kasutamise programmist (AD1117064; N=3) said ravi Strimvelis’ega kokku 18 ADA-SCID patsienti.
A total of 181 patients were treated and evaluable for efficacy (91 with Eylea).
Uuringus raviti kokku 181 patsienti (91 patsienti Eylea’ga), kes kõik vastasid efektiivsuse hindamise tingimustele.
A total of 184 infusions of Coagadex were given as a preventative measure.
Ennetavalt tehti kokku 184 Coagadex’i infusiooni.
A total of 1935 patients were randomised to double- blind medication and approximately 70% were also using a long-acting muscarinic antagonist (LAMA) through the course of the trial.
Topeltpimedas uuringus randomiseeriti ja raviti kokku 1935 patsienti ja ligikaudu 70% neist kasutas uuringu käigus ka LAMA.
A total of 197 patients aged 15 years or older with severely, active granulomatosis with polyangiitis (75%) and microscopic polyangiitis (24%) were enrolled and treated in an active-comparator, randomised, double-blind, multicenter, non-inferiority trial.
Aktiivse võrdlusravimiga randomiseeritud topeltpimedas platseebokontrollitud mitmekeskuselises samaväärsuse uuringus osales ja sai ravi kokku 197 raske ägeda granulomatoosse polüangiidi (75%) ja mikroskoopilise polüangiidiga (24%) patsienti alates 15 aasta vanusest.
A total of 199 (35.2%) of all patients were not evaluable for MMR at 36 months (87 in the nilotinib 300 mg twice daily group and 112 in the imatinib group) due to missing/unevaluable PCR
36. kuul ei olnud kokku 199-l (35,2%) kõigist patsientidest MMR hinnatav (87-l nilotiniib 300 mg kaks korda ööpäevas rühmas ja 112-l imatiniibi rühmas) puuduva/mittehinnatava PCR määramise (n=17), algtaseme ebatüüpilise transkripti (n=7) või enne
A total of 2 malignancies were reported in clinical studies of approximately 2 years duration involving 240 Enbrel-treated psoriatic arthritis patients.
240-l psoriaatilise artriidiga patsiendil läbi viidud, ligikaudu 2 aastat väldanud Enbreli kliinilise uuringu käigus avastati kaks pahaloomulisuse juhtu.
A total of 2,106 patients received insulin glargine 100 units/ml in all trials combined.
Kõigis uuringutes kokku manustati glargiininsuliini 100 U/ml 2106 patsiendile.
A total of 2,114 patients were treated in the active controlled DVT/PE prevention trial, RE-MEDY, and in the placebo-controlled DVT/PE prevention trial, RE-SONATE.
Aktiivse kontrolliga SVT/PE profülaktika uuringus RE-MEDY ja platseebokontrolliga SVT/PE sekundaarse preventsiooni profülaktika uuringus RE-SONATE raviti kokku 2114 patsienti.
A total of 2,114 patients were treated in the active controlled DVT/PE prevention trial, RE-MEDY, and in the placebo-controlled DVT/PE prevention trial, RE-SONATE.
Aktiivse kontrolliga SVT/PE profülaktika uuringus RE-MEDY ja platseebokontrolliga VTE sekundaarse preventsiooni profülaktika uuringus RE-SONATE raviti kokku 2114 patsienti.
A total of 2,365 patients with type 2 diabetes were treated with Eperzan and 2,530 received other study medications in 8 active and placebo-controlled phase III clinical trials.
8 aktiivse ja platseebokontrolliga III faasi kliinilises uuringus raviti Eperzan’iga kokku 2365 II tüüpi diabeediga patsienti ja 2530 patsienti said teisi uuringuravimeid.
A total of 2,866 patients were randomized and 2,856 patients were treated.
Kokku randomiseeriti 2866 patsienti ning raviti 2856 patsienti.
A total of 20 subjects (12 T/LAIV, 0.3%; 8 injectable influenza vaccine, 0.2%) were hospitalized in association with medically significant wheezing.
Seoses kliiniliselt olulise viliseva hingamisega hospitaliseeriti kokku 20 osalejat (12 T/LAIV, 0,3%; 8 süstitav gripivaktsiin, 0,2%).
A total of 201 Cushing’s disease patients received Signifor in phase II and III studies.
ja III faasi uuringutes manustasid Signifor’i kokku 201 Cushingi tõvega patsienti.
A total of 207 patients were treated with Revatio in the pivotal study, and their long term survival status was assessed for a minimum of 3 years.
Algses pöördelise tähtsusega uuringus raviti Revatioga kokku 207 patsienti ja nende pikaajalist elulemust hinnati minimaalselt 3 aasta jooksul.
A total of 211 adult and paediatric CAPS patients (including FCAS/FCU, MWS, and NOMID/CINCA) have received Ilaris in clinical trials.
Kliinilistes uuringutes on Ilaris’t saanud kokku 211 krüopiriiniga seotud perioodiliste sündroomidega täiskasvanut ja last (sh FCAS/FCU, MWS ja NOMID/CINCA).
A total of 213 patients (48.3%) completed ≥ 6 cycles and a total of 103 patients (23.4%) completed ≥ 10 cycles of treatment with pemetrexed.
213 patsienti (48,3%) ja ≥ 10 ravitsüklit pemetrekseediga sai kokku 103 patsienti (23,4%).
A total of 217 subjects aged 18-65 years received IXIARO together with inactivated rabies vaccine (Rabipur) in a rapid immunisation schedule on Day 0 and Day 7 and 56 subjects received IXIARO alone in the conventional immunisation schedule on Day 0 and Day 28.
IXIAROt manustati koos inaktiveeritud marutaudi vaktsiiniga (Rabipur) kokku 217 uuritavale vanuses 18–65 eluaastat immuniseerimise kiirskeemi alusel päeval 0 ja 7. päeval ning 56 uuritavale manustati ainult IXIAROt immuniseerimise tavaskeemi alusel päeval 0 ja 28. päeval.
A total of 2184 patients were treated; for both groups, patients were treated for at least 5 days and up to 22 days (mean 7 days).
Kokku raviti 2 184 patsienti; kummaski grupis kestis ravi vähemalt 5 päeva ja kuni 22 päeva (keskmine 7 päeva).
A total of 2184 patients were treated; for both groups, patients were treated for at least 5 days and up to 22 days (mean 7 days).
Kokku raviti 2184 patsienti; kummaski grupis kestis ravi vähemalt 5 päeva ja kuni 22 päeva (keskmine 7 päeva).
A total of 22 paediatric and adolescents patients (aged 5 months to 17 years) received Soliris in aHUS Study C10-003.
aHUS-i uuringus C10-003 manustati Soliris’t kokku 22 lapsele ja noorukile (vanuses 5 kuud kuni 17 aastat).
A total of 225 patients aged ≥ 18 years of age with relapsed or refractory B-precursor ALL were exposed to BLINCYTO during clinical trials.
BLINCYTO kliinilistes uuringutes osales kokku 225 patsienti vanuses ≥ 18 aastat, kellel oli retsidiveerunud või refraktaarne B-eellasrakuline ALL.
A total of 225 patients were treated with subcutaneous Ilaris 150 mg and 229 patients were treated with intramuscular triamcinolone acetonide (TA) 40 mg at study entry, and when experiencing a new attack thereafter.
Kokku raviti 225 patsienti Ilaris’ega 150 mg subkutaanselt ja 229 patsienti triamtsinoloonatsetoniidiga (TA) 40 mg intramuskulaarselt, uuringu alguses ja seejärel uue hoo korral.
A total of 226 (74.8%) of the Pom + LD-Dex patients and 95 (62.1%) of the HD-Dex patients were alive as of the cutoff date (07 Sep 2012).
Andmete lõppkuupäevaks (07. september 2012) oli elus 226 patsienti (74,8%) POM + LD-Dex rühmas ja 95 patsienti (62,1%) HD-Dex rühmas.
A total of 23/99 (23%) MabThera-treated patients in the trial tested positive for HACA by 18 months.
18. kuul olid inimese antikimäärsete antikehade (HACA) suhtes positiivsed kokku 23% (23/99) uuringus osalenud MabThera’ga ravitud patsientidest.
A total of 233 PASI 75 responders at Week 16 and Week 33 received continuous Humira therapy for 52 weeks in Psoriasis Study I, and continued Humira in the open-label extension trial.
233 patsienti PASI 75 tulemusega 16. ja 33. nädalal said psoriaasi uuringu I käigus jätkuvat Humira- ravi 52 nädala jooksul ning jätkasid avatud jätku-uuringus.
A total of 233 PASI 75 responders at Week 16 and Week 33 received continuous Humira therapy for 52 weeks in Psoriasis Study I, and continued Humira in the open-label extension trial.
233 patsienti PASI 75 tulemusega 16. ja 33. nädalal said psoriaasi uuringu I käigus jätkuvat Humira-ravi 52 nädala jooksul ning jätkasid avatud jätku-uuringus.
A total of 235 patients with MPS IVA were enrolled and exposed to Vimizim in six clinical trials.
Kuude kliinilisse uuringusse kaasati kokku 235 IVA-tüüpi mukopolüsahharidoosiga patsienti, kes said Vimizimi.
A total of 2378 adult patients with severe sepsis received drotrecogin alfa (activated) in a Phase 3b, international, single-arm, open-label clinical trial (ENHANCE).
3.b faasi rahvusvahelises, ühe ravigrupiga, avatud kliinilises uuringus (ENHANCE) said kokku 2378 raske sepsisega täiskasvanud patsienti α-drotrekogiini (aktiveeritud).
A total of 238 postmenopausal women, were randomly assigned to one of the following treatment groups; Preotact (100 micrograms parathyroid hormone), alendronate (10 mg), or the combination of both, and followed for 12 months.
Kokku 238 postmenopausis naist randomiseeriti esimeseks 12 kuuks kolme ravigruppi: Preotact (100 mikrogrammi parathormooni), alendronaat (10 mg) või Preotact’i ja alendronaadi kombinatsioonravi.